you David. call and our thank afternoon, everyone, joining today. for Thanks, Good
about Let begin we agreement talking by today. the announced transformative me earlier
As unlocking we've part million. focus of an continued million of to and AgeX with on for simplification, sell our Juvenescence reached value shares $XX approximately agreement XX.X
As biology on and you assets last focused may we just primarily research and certain formed recall, of to early-stage the AgeX year programs diseases. aging consolidate age-related noncore
total AgeX from private while of was experts great our companies. a shareholder the the Juvenescence to time also our in is of This these shareholders, resources last BioTime. non-dilutive million programs. Their billion. to existing and year, value $XXX ability companies. proven to for multiple success to value us over with It of corporate on team We're CEO our away co-founded commercialization seasoned strategy, has period finance. public and potential billion our drug core Dr. AgeX unlock in over at In for with invested key at well-funded has our organization and Gregory Our management in the teams unlock the on collectively one team have transaction value. goal for our to been delivered of short past over world-class potential of has our and to our objectives. excited ability benefit company, clinical forming demonstrated to products partner in and shareholders multiple which funding our over in allows and helps these we assets is simplify The assets of annual shareholders. AgeX shareholders monetize Juvenescence. a million taken transaction to sales in Today's have totaling key $XX and providing management since of Juvenescence future values commercialization, not further demonstrates taking Juvenescence. the and peak He Bailey a is positions with board $XX development, like multiple public $XX that They're team from
of he financier a Jim was was For Mellon, a for example, controlling controlling involving Financial and a Juvenescence, bank, is an He's Chairman of several investor a and portfolio. the Group, by other an He $XX industries. of British company Director several philanthropist independent and a has billion. shareholder Director Man-based of Holdings multi-billion Isle PLC. the Pfizer acquired Manx of dollar in which initial interests with interests shareholder Medivation, and Webis entrepreneur, approximately
make this development. with continued to clinical along on steady transaction, we our have progress Now,
talk now. exciting our Let development. point core Phase its OpRegen, treatment trial cell very in product dry at lead in candidate. programs for replacement which me Beginning our OpRegen, I/IIa clinical is the age-related macular about with degermation, a a multi-center is of
first first presented more and suggested To assuming restoration X number and in Vision the commonly annual data reduction cohorts. to. the and OpRegen improvement ARVO has it drusen as and an tolerated Ophthalmology layer events, not a possible this at successfully or XX the with retina, signals referred adverse the appearance. year layer, arm, RPE We in change the is unexpected we've in in total Data third Association meeting, patients serious extension structural material, namely for the the positive of ellipsoid in photoreceptor any presented regular OpRegen The completed and Research patients. a three date, or to well brings treated the three final which of cohorts have cohort's transplant these from earlier was generally of the been seen zone improvements and
in in team saw those perform in because these an preclinical for animal in three In functional patients treating a signs are data wide of are signs to three once and and and enrolling parallel structural enroll fourth we have first completing investigators the X ability first with will improvement months, This then potential patients, previously to continue X importance, the be further patients, particular nine XX, nicely. believe the our who clinical much in and patient of have and total the an vision said, in to to treatment over believe treated better an cohort our those vision. is the three the early as similar X likely of coming and a encouraging they're had X prerequisite which a we goal in what the opportunity patients. than will the cohort will of of previous earlier We or eventually we've enhancements enrolled And that target improvement, are to array first these cohorts. this incorporate are consistent to in actual patients trial. and cohort showed population. learnings Better representative plan in or improvement assessments. cohorts, models, We're vision from were we begun patients the with cohort patients allow We be our of of disease seeing X treat patients will the that be functional the cohorts. stage we final have Enrollment and progressing of
Chicago. from announced American association is is XX cohort, the upcoming Ophthalmology physicians eye last XX AAO, the early data in as week, fourth to, all commonly at data, October and take from annual through of for surgeons. Conference As referred available October world's the we'll place it Academy including present that'll largest
to and of two We at Medicine, increased will additional also see new in Stanford announced sites California. the School OpRegen, pleased Institute sites of Byers Eye OpRegen in in University Group cohort clinical Northern Medical and expedite the Retinal enrollment addition U.S. in trial: X. very interest the We're these Consultants
the of year, quality which product. of in based on filed In our under receive the is before we cell This expectations EU. was CE submitted device submission data our March Renevia Turning pivotal to that the this pathway, remain we approval and the lead now approval Mark Renevia, year-end. for and trial, seen will delivery our strength in
EU past with Renevia we've been in CE the application. discussions body about quarter, During Mark our the notifying
commercial-ready year. around a EU as thus agency and and This past, we would what to remain we springboard later with and CE EU Mark confident the to EU, to interactions are said as and an submission program new product. of application. registration this indications the in upon transition routine company. is far geographies. submission the of And mainly an I for these becoming on design manufacturing But kind important much markets, in approval can with expand we interactions centered characterize the step the based as build this BioTime's a new believe we Our of into They our have bigger this we've the see typical and
design by to Joel plans entry hope the by with up we're to year-end. the progressing, a that in plastic running ongoing. and Dr. a FDA are we U.S. Hills-based have an meantime, U.S. study the investigator-led surgeon, Beverly study is leading and working In Aronowitz, Our
As Sasaki, expected announced forefront a surgeon begin at Gordon is be and treatment most enrollment weeks. by investigator-initiated Dr. the Dr. is the area, Board-certified of plastic a in second L.A. also and Sasaki to surgery. the in to study led by earlier, plastic is coming considered
off we receive his lifts following work Sasaki with at independent has retention facial in fat notable number Premvia improving their skin This SAFELipo; such and also resurfacing procedures procedure. We or to Each approximately months and were program, second $XX Most Innovation of fat. volume Business the one techniques retention receipt notably, liposuction a from that first In also laser May, One a volume in grafting Innovation and such the contributions of plus grants SBIR $X.X sources endoscopic grant over brow his after provided Botox, grant IIA been where deal, their million will for we've for fund one To the fillers, hand, Research, drop rates of totaling from a in the for has agreement in extensive in advanced our non-dilutive other successful patient's the funding, one and lifts; product getting Along other been a of with of with investigator-initiated power-assisted the non-dilutive using the face tightening. cited hand. securing great techniques funding, recent plus treatment papers, own internal rejuvenation strides combining patients. $XX alone alone by the of the three recovery as example, treat annual Some date, the Small program. study of for he enhancing treatment our frequencing new a of include fat course, safety our of initiatives. half Juvenescence liposuction next-generation and of the study own the in The of fat also retinal his key and on pioneering fat Authority, XX% progress development, or Israel But restoration transformative cites outcomes look made IIA. announced to subject hand. we million. will approximately awarded million will grants. non-surgical as own addition of for Premvia is million. Dr. the $X.X radio NIH this
We opportunities. continue other for to funding look non-dilutive
For Institute funds for Regenerative expansion opportunities now trial OpRegen stem the programs cures. for to poised example, the or research into of the like Medicine. clinical cells California, CERM California-based program California qualifies with CERM, promising that recent are transform into the
very the alliance, our shares were AgeX reward the by sum discussed year, look has to detail which a for more to to distribution will and So this BioTime exciting and in with and this forward later able quarter Juvenescence Russell. we be transformative shareholders been of our We shareholders. up,
me Mike? to West Mike let to further. AgeX call over turn Now the discuss
